We have collected information about Cellular Delivery In Vivo Of Sirna Based Therapeutics for you. Follow the links to find out details on Cellular Delivery In Vivo Of Sirna Based Therapeutics.
https://www.ncbi.nlm.nih.gov/pubmed/19075737
1. Curr Pharm Des. 2008;14(34):3603-19. Cellular delivery in vivo of siRNA-based therapeutics. Aigner A(1). Author information: (1)Department of Pharmacology and Toxicology, Philipps-University, School of Medicine, Karl-von-Frisch-Strasse 1, D - 35032 Marburg, Germany. [email protected] RNAi interference (RNAi) is an almost standard method for the knockdown of any target gene of ...Author: A. Aigner
https://www.ingentaconnect.com/contentone/ben/cpd/2008/00000014/00000034/art00002
Cellular Delivery In Vivo of siRNA-Based Therapeutics Buy Article: $68.00 + tax ... (siRNA), and thus siRNA delivery in vivo is of critical importance for its implementation. Due to the instability and physicochemical properties of siRNAs, the development of strategies and formulations for siRNA protection, cellular uptake, correct ...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378126/
Mar 16, 2009 · Targeted cellular delivery. Targeted delivery is another important goal for siRNA therapeutics. Positively charged protamine peptides have been conjugated to single chain antibodies targeting various cellular receptors, including ERB2, HIV gp120 and the lymphocyte specific LFA1 receptor (Peer et al, 2007; Song et al, 2005).Author: Katrin Tiemann, John J. Rossi
http://www.eurekaselect.com/68231
Keywords:RNA interference, small interfering RNA, RNAi, siRNA, gene targeting in vivo, polyethylenimine, in vivo siRNA delivery. Abstract: RNAi interference (RNAi) is an almost standard method for the knockdown of any target gene of interest in vitro, exploring a naturally occurring catalytic mechanism. Beyond functional analyses, the ...Author: A. Aigner
https://www.sciencedirect.com/science/article/pii/S0169409X15000095
Initial studies were conducted in diseases requiring localized delivery. Later, with the improvements in nanocarrier technology, systemically delivered siRNA-based therapeutics outnumbered the ones locally delivered , . An overview of clinical trials using siRNA-based therapeutics delivered by different methods is provided here. 3.1.Author: Gulnihal Ozcan, Bulent Ozpolat, Robert L. Coleman, Anil K. Sood, Gabriel Lopez-Berestein
https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(16)30083-X
However, their full effectiveness in cells and in vivo has often only been realized through development of suitable nonviral delivery systems. Among these, a range of natural and synthetic peptides have been found useful for enhancing cellular uptake and/or cell targeting of oligonucleotide analogues and siRNA.
https://www.sciencedirect.com/science/article/pii/S0169409X19300547
A few polymer-based siRNA delivery systems have shown therapeutic potential in clinical trials . Examples of major classes of polymer-based delivery systems are discussed below. 7. siRNA-polymer bioconjugates. Direct conjugation of siRNA to polymers offers an attractive avenue to improve stability, pharmacokinetics, cellular uptake, and delivery.Author: Yizhou Dong, Daniel J. Siegwart, Daniel G. Anderson
https://onlinelibrary.wiley.com/doi/full/10.1002/lio2.310
Our laboratory recently described both in vivo and in vitro utility of a novel synthetic oligomer, lipitoid L0, complexed with siRNA to improve stability and cellular uptake with the goal of increased efficiency of RNA‐based therapeutics. We were the first group to show preclinical data regarding the efficacy of RNA‐based therapeutics to ...Author: Shigeyuki Mukudai, Iv Kraja, Renjie Bing, Danielle M. Nalband, Mallika Tatikola, Nao Hiwatashi, Kent...
https://altogen.com/transfection-resource/rnai-therapeutics/
Therefore, our research is focused on the development of efficient in vivo reagents and RNAi delivery technologies. Efficient and organ-specific delivery of synthetic oligonucleotide molecules is currently a key limiting step to enable siRNA- and microRNA-based therapeutic approaches. In Vivo Transfection Kits from Altogen Biosystems
https://www.nature.com/articles/nmat3765
Oct 23, 2013 · Therapeutics based on small interfering RNA (siRNA), which in principle are able to reversibly silence any gene of interest, are under development for the …Author: Rosemary Kanasty, Joseph Robert Dorkin, Arturo Vegas, Arturo Vegas, Daniel Anderson
Searching for Cellular Delivery In Vivo Of Sirna Based Therapeutics?
You can just click the links above. The data is collected for you.
